Home > Insider Trading > Filing (0001415889-23-000638)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479419	Kala Pharmaceuticals Inc.	KALA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1298079	K Romulus Brazzell	C/O Kala Pharmaceuticals, Inc. 1167 Massachusetts Avenue Arlington MA 02476	See Remarks	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-01-04	12,800	$0.00	18,609	No	4	A	Direct
Common Stock	Disposition	2023-01-04	73	$28.53	18,536	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.
Includes 13,167 unvested RSUs.
This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.59, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Includes 12,984 unvested RSUs.